Reprocell Acquires Reinnervate and BioServe
News Aug 05, 2014
Reinnervate Ltd has been acquired by Reprocell of Shin-Yokohama in Japan. Reprocell intends to combine it’s iPSC-derived cells with the Alvetex range of 3D cell culture products to produce and sell next-generation tools for drug toxicity testing, neuroscience and cancer research.
Reprocell also announced the acquisition of BioServe Inc of MD, USA, a leading supplier of human tissues and other biological samples with one of the largest commercial biorepositories in the world. BioServe also offer a range of services including, genotyping, gene expression and allelic discrimination (RT PCR).
Reprocell plans to use the unparalleled access to human tissues to generate a wide range of disease-related iPSC lines for production of human disease cell models.
Commenting on the deal, Reinnervate Ltd CEO. Richard Rowling, said ‘We are delighted to become part of the Reprocell group of companies and look forward seeing Alvetex products combined with Reprocell’s advanced stem cell derived cell products. Our customers are always looking for ways to improve the biological relevance of cell based assays and to move away from using cell lines. Combining the benefits offered by iPSC-derived cells and 3D cell culture will lead to exciting new product introductions’.
Chika Yokoyama, CEO of Reprocell added, ‘The Reprocell group of companies now offers products and services that span the 2D and 3D cell culture, stem cell culture media, iPSC-derived cells and human tissue samples. We can now help the global scientific community move their basic and pre-clinical research towards more sustainable and physiologically relevant models. Our customers can now move easily from testing monolayer culture to 3D culture to human tissue systems all with support from a single source.’
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019